To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

July 30, 2018

Today's Rundown

Featured Story

RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3

A phase 3 trial of RedHill Biopharma’s Crohn’s disease asset has met its primary endpoint. The study linked antibiotic cocktail RHB-104 to a higher rate of remission than placebo after 26 weeks, although the difference between the two arms shrunk later in the trial.

Top Stories

Lilly firms up cancer collaboration with Dana-Farber

Eli Lilly must be seeing value in its broad-ranging research collaboration with the Dana-Farber Cancer Institute, as it’s extending the partnership for another three years.

Sienna slumps as acne asset flunks phase 3 trials

Sienna Biopharmaceuticals’ acne candidate SNA-001 has comprehensively failed two phase 3 trials. The addition of the silver particle treatment to laser light therapy failed to improve outcomes against three key endpoints, leaving the future of Sienna’s most advanced candidate in doubt.

After its recent funding round, HiFiBiO pens Takeda R&D collaboration

HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda to work on antibody therapies for various gastrointestinal diseases, cancers and other disorders.

Freshly funded IFM Therapeutics defines emerging target for fighting inflammatory disease

Just two weeks after hauling in a $31 million series A funding round to form a new subsidiary, Boston-based IFM Therapeutics is laying out a case for the unit’s primary drug target: a signaling receptor called NLRP3. Blocking NLRP3 could treat a range of autoimmune disorders, including Crohn’s and Alzheimer’s.

Startup aims to use AI to spot connections in published research

A London-based artificial intelligence startup raised $1 million in seed funding to develop automated “machine reading” programs that aim to digest and distill the expansive mass of documents in biomedical literature and research.

Resources

[Survey] Industry Report: Findings from the 2018 Unified Clinical Operations Survey

Industry Research: See new results from one of the industry's largest, global clinical operations surveys.

[Whitepaper] How early planning and a unified data platform can cut trial timelines and cost.

Accelerate Clinical Research as Study Complexity Grows

[Whitepaper] Building the Business Case for RIM Transformation

Ready to modernize your RIM environment? Secure buy-in with these tips.

[Whitepaper] Rise in Targeted Therapies Drives Needs for Small Volume Manufacturing

Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy.

[Whitepaper] eClinical Landscape Study - CRO Report from Tufts Center for the Study of Drug Development

See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs).

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

Events

.